Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2007

01-04-2007 | Article

Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy

Authors: J. Gómez, E. García-Vázquez, R. Baños, M. Canteras, J. Ruiz, V. Baños, J. A. Herrero, M. Valdés

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2007

Login to get access

Abstract

The objective of this study was to evaluate prognostic factors and the influence of different empiric antibiotic therapies on outcome and mortality in a cohort of 100 inpatients with bacteraemia (84 cases nosocomial) caused by methicillin-resistant Staphylococcus aureus (MRSA). Patients were investigated by means of a standard protocol at a 944-bed hospital in the years 2000–2004. Empiric antibiotic therapies included vancomycin (n = 49), teicoplanin (n = 20), linezolid (n = 17), other antibiotics active in vitro (n = 7), and inactive antibiotics (n = 7). Overall mortality was 40% (12% among linezolid-treated patients; 46.3% among glycopeptide-treated patients). In bivariate analyses, the following factors were statistically associated with higher mortality: rapidly fatal underlying disease, altered mental status, metabolic acidosis, and acute severe clinical condition at the onset of bacteraemia; development of complications (septic shock, renal failure, and disseminated intravascular coagulopathy); empiric monotherapy with glycopeptides (vs combination therapy with an aminoglycoside); and inadequate empiric treatment. Empiric therapy with linezolid was associated with lower mortality. In multivariate analysis, risk factors associated with higher mortality included acute severity of illness (OR 7.49; 95%CI 1.19–25.3) and altered mental status (OR 4.83; 95%CI 1.22–19.15) at onset, complications (OR 3.42; 95%CI 1.02–17.46), and inappropriate empiric treatment (OR 7.6; 95%CI 1.87–31.14). In multivariate analysis limited to patients who received empiric therapy with either linezolid (n = 17) or glycopeptides (n = 69), linezolid was associated with greater rates of survival (OR 7.7; 95%CI 1.1–53) and microbiological eradication (OR 11.76; 95%CI 1.46–90.9) but not with fewer complications (OR 0.71; 95%CI 0.16–3.25). In conclusion, the main prognostic factors associated with mortality in patients with MRSA bacteraemia are complications, acute severe clinical condition at onset, and inappropriate empiric treatment. Empiric therapy with linezolid was associated with greater survival and more successful microbiological eradication but did not reduce complications.
Literature
1.
go back to reference Selvey L, Whitby M, Johnson B (2000) Nosocomial methicillin-resistant S. aureus bacteraemia: is it any worse than nosocomial methicillin-sensitive S. aureus bacteraemia? Infect Control Hosp Epidemiol 21:645–648PubMedCrossRef Selvey L, Whitby M, Johnson B (2000) Nosocomial methicillin-resistant S. aureus bacteraemia: is it any worse than nosocomial methicillin-sensitive S. aureus bacteraemia? Infect Control Hosp Epidemiol 21:645–648PubMedCrossRef
2.
go back to reference Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N Monen J, Witte W, Grundman H, and the European Antimicrobial Resistance Surveillance System Participants (2004) Methicillin-resistant S. aureus in Europe, 1999–2002. Emerg Infect Dis 10:1627–1634PubMed Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N Monen J, Witte W, Grundman H, and the European Antimicrobial Resistance Surveillance System Participants (2004) Methicillin-resistant S. aureus in Europe, 1999–2002. Emerg Infect Dis 10:1627–1634PubMed
3.
go back to reference Oteo J, Cruchaga S, Campos J, Sáez JA, Baquero F, and Spanish Members of the European Antimicrobial Resistance Surveillance System (EARSS) (2002) Resistencia a antibióticos en S. aureus aislados de sangre en 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Med Clin 119:361–365 Oteo J, Cruchaga S, Campos J, Sáez JA, Baquero F, and Spanish Members of the European Antimicrobial Resistance Surveillance System (EARSS) (2002) Resistencia a antibióticos en S. aureus aislados de sangre en 31 hospitales españoles de la Red Europea de Vigilancia de Resistencia a Antibióticos (2000). Med Clin 119:361–365
4.
go back to reference Cosgrove SE, Sakoulas G, Perencevich EN, Schawer MJ, Karchmer AW (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteraemia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRef Cosgrove SE, Sakoulas G, Perencevich EN, Schawer MJ, Karchmer AW (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteraemia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRef
5.
go back to reference Soriano A, Martínez JA, Mensa J, Marco F, Almela M, Moreno-Martínez A, Sánchez F, Muñoz I, Jiménez de Anta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with S. aureus bacteraemia. Clin Infect Dis 30:368–373PubMedCrossRef Soriano A, Martínez JA, Mensa J, Marco F, Almela M, Moreno-Martínez A, Sánchez F, Muñoz I, Jiménez de Anta MT, Soriano E (2000) Pathogenic significance of methicillin resistance for patients with S. aureus bacteraemia. Clin Infect Dis 30:368–373PubMedCrossRef
6.
go back to reference Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired S. aureus bacteraemia. Clin Infect Dis 36:1418–1423PubMedCrossRef Lodise TP, McKinnon PS, Swiderski L, Rybak MJ (2003) Outcomes analysis of delayed antibiotic treatment for hospital-acquired S. aureus bacteraemia. Clin Infect Dis 36:1418–1423PubMedCrossRef
7.
go back to reference Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O’Donnell A, Wagener MM, Yu VL (2003) A prospective multicenter study of S. aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 82:322–332PubMedCrossRef Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O’Donnell A, Wagener MM, Yu VL (2003) A prospective multicenter study of S. aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 82:322–332PubMedCrossRef
8.
go back to reference Garnes JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef Garnes JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef
9.
go back to reference McCabe WR, Jackson GG (1962) Gram-negative bacteraemia. Etiology and ecology. Arch Intern Med 110:847–855 McCabe WR, Jackson GG (1962) Gram-negative bacteraemia. Etiology and ecology. Arch Intern Med 110:847–855
10.
go back to reference Winston DJ, Murphy W, Young LS, Hewitt WL (1980) Piperacillin therapy for serious bacterial infections. Am J Med 69:255–261PubMedCrossRef Winston DJ, Murphy W, Young LS, Hewitt WL (1980) Piperacillin therapy for serious bacterial infections. Am J Med 69:255–261PubMedCrossRef
11.
go back to reference Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimødt-Møller N (2002) Treatment and outcome of S. aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 162:25–32PubMedCrossRef Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimødt-Møller N (2002) Treatment and outcome of S. aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 162:25–32PubMedCrossRef
12.
go back to reference Blot S, Vandewoude K, Hoste E, Colardyn F (2002) Attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant S. aureus. Arch Intern Med 162:2229–2235PubMedCrossRef Blot S, Vandewoude K, Hoste E, Colardyn F (2002) Attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant S. aureus. Arch Intern Med 162:2229–2235PubMedCrossRef
13.
go back to reference Blot S (2005) MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 33:2127–2128PubMedCrossRef Blot S (2005) MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 33:2127–2128PubMedCrossRef
14.
go back to reference Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant S. aureus bacteraemia. J Clin Microbiol 42:2398–2402PubMedCrossRef Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant S. aureus bacteraemia. J Clin Microbiol 42:2398–2402PubMedCrossRef
15.
go back to reference Knatib R, Riederer KM, Held M, Aljundi H (1995) Protracted and recurrent methicillin-resistant S. aureus bacteraemia despite defervescence with vancomycin therapy. Scand J Infect Dis 27:529–532 Knatib R, Riederer KM, Held M, Aljundi H (1995) Protracted and recurrent methicillin-resistant S. aureus bacteraemia despite defervescence with vancomycin therapy. Scand J Infect Dis 27:529–532
16.
go back to reference Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML (2004) Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate S. aureus. Clin Infect Dis 38:448–451PubMedCrossRef Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML (2004) Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate S. aureus. Clin Infect Dis 38:448–451PubMedCrossRef
17.
go back to reference Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394PubMedCrossRef Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394PubMedCrossRef
18.
go back to reference Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760–766PubMedCrossRef Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760–766PubMedCrossRef
19.
go back to reference Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for S. aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929PubMedCrossRef Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for S. aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929PubMedCrossRef
20.
go back to reference Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, Müller S, Krönke M (2004) Subinhibitory concentrations of linezolid reduce S. aureus virulence factors expression. Antimicrob Agents Chemother 48:546–555PubMedCrossRef Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, Müller S, Krönke M (2004) Subinhibitory concentrations of linezolid reduce S. aureus virulence factors expression. Antimicrob Agents Chemother 48:546–555PubMedCrossRef
Metadata
Title
Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy
Authors
J. Gómez
E. García-Vázquez
R. Baños
M. Canteras
J. Ruiz
V. Baños
J. A. Herrero
M. Valdés
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0272-x

Other articles of this Issue 4/2007

European Journal of Clinical Microbiology & Infectious Diseases 4/2007 Go to the issue